Childhood-Onset Myasthenia Gravis Patients Benefited from Thymectomy in a Long-Term Follow-up Observation.
Childhood-Onset Myasthenia Gravis Patients Benefited from Thymectomy in a Long-Term Follow-up Observation.
复制标题
在长期随访观察中,儿童期重症肌无力患者受益于胸腺切除术
DOI:
10.1055/s-0042-1744150
复制
发表时间:
2022-12
影响因子:
1.8
通讯作者:
Bu, Bitao
中科院分区:
文献类型:
--
作者:
Zhang, Qing;Cao, Yayun;Bi, Zhuajin;Ma, Xue;Yang, Mengge;Gao, Huajie;Gui, Mengcui;Bu, Bitao
Introduction The effect of thymectomy on the treatment of childhood-onset myasthenia gravis (CMG) remains debatable. The objective of this study was to evaluate the clinical outcome and relevant prognostic factors of thymectomy for CMG patients. Materials and Methods A total of 32 CMG patients who underwent thymectomy before 18 years of age were included in this retrospective study. Clinical state following thymectomy was assessed by quantified myasthenia gravis (QMG) scores, myasthenia gravis–related activities of daily living (MG-ADL) scores, and Myasthenia Gravis Foundation of America postintervention status. Repeated-measures analysis of variance (ANOVA) examined the changes in postoperative scores during the 5-year follow-up. Univariate logistic regression was applied to identify factors associated with short-term (1-year postoperation) and long-term (5-year postoperation) clinical outcomes. Results Repeated-measures ANOVA showed that QMG scores ( F = 6.737, p < 0.001) and MG-ADL scores ( F = 7.923, p < 0.001) decreased gradually with time. Preoperative duration (odds ratio [OR] = 0.85, 95% confidence interval [CI]: 0.73–1.00, p = 0.043), gender (OR = 0.19, 95% CI: 0.04–0.94, p = 0.041), and MG subgroup (OR = 13.33, 95% CI: 1.43–123.99, p = 0.023) were predictors for 1-year postoperative prognosis. Shorter disease duration (OR = 0.82, 95% CI: 0.70–0.97, p = 0.018) and generalized CMG (OR = 6.11, 95% CI: 1.06–35.35, p = 0.043) were found to have more favorable long-term results. Conclusion Our results suggest that thymectomy is effective in treating CMG. Thymectomy could be recommended for CMG patients, especially for patients in the early course of GMG.
登录
查看更多内容
影响因子:
2.4
作者:
Derderian, S. Christopher;Potter, D. Dean;Partrick, David A.
通讯作者:
Partrick, David A.
影响因子:
4.6
作者:
Endo, S;Yamaguchi, T;Sohara, Y
通讯作者:
Sohara, Y
影响因子:
3.4
作者:
Essa, M;El-Medany, Y;Al-Kattan, K
通讯作者:
Al-Kattan, K
影响因子:
3.5
作者:
Huang, CS;Hsu, HS;Huang, MH
通讯作者:
Huang, MH
DOI:
10.1016/s0022-5223(96)70264-7
发表时间:
1996-08-01
影响因子:
6
作者:
Nakamura, H;Taniguchi, Y;Mori, T
通讯作者:
Mori, T